The 12th International Symposium on Targeted Alpha Therapy will provide information on the newest developments in preclinical studies, clinical experiences, dosimetry and instrumentation, quality assurance, regulatory, targeting, radiochemistry, and nuclide production and supply.
Full programme available on the event website.
Online registration is open:
- nuclear research
The JRC is co-organising from 27 February to 2 March 2023 in South-Africa, the 12th International Symposium on Targeted Alpha Therapy (TAT 12). TAT 12 continues a successful series of international symposia on this topic initiated by the Joint Research Centre of the European Commission in Karlsruhe in 1997 and 2000.
This year, colleagues Alfred Morgenstern will be the co-chair of the symposium together with Prof. Mike Sathekge from the University of Pretoria; Frank Bruchertseifer will lead the scientific committee with Mariza Vorster from the University of KwaZulu-Natal.
Previous TAT international symposia
TAT 12 continues a successful series of international symposia on this topic initiated by the Joint Research Centre of the European Commission, including meetings in Karlsruhe (1997, 2000), Heidelberg (2002), Düsseldorf (2004), Aachen (2007), Toronto (2009), Berlin (2011), Oak Ridge (2013), Warsaw (2015), Kanazawa (2017) and Ottawa (2019).
For more information, visit TAT12 International Symposium (tat-12.com)
Call for Abstracts
The Scientific Committee invites all interested colleagues to submit oral and/or poster abstracts for the TAT 12 Symposium. The symposium offers an excellent opportunity to network and to share the most up-to-date research in the field of Targeted Alpha Therapy.
View and Download the Call for Abstracts
Alpha Therapy: nuclear waste gives precious lifetime to cancer patients
Nuclear waste helps cancer patients. You find it hard to believe? Discover Targeted Alpha Therapy in this video.